Navigation Links
Repair Stem Cell Institute Announces Science Advisory Board

DALLAS, July 16 /PRNewswire/ -- The Repair Stem Cell Institute LLC (RSCI;, a Dallas, Texas-based stem cell global public affairs organization, today announced the formation of a new Science Advisory Board (SAB) consisting of some of the world's leading stem cell medical, science and research professionals. RSCI was founded in April 2008 and has offices located in Washington, D.C. and Bangkok.

According to Don Margolis, RSCI chairman and founder (; 214-556-6377), "RSCI's new Science Advisory Board has been created to provide the general public with the latest repair stem cell research and therapeutic innovations. Each of these five SAB members are active stem cell leaders who are not only researching, but successfully delivering cells to patients suffering from heart disease, diabetes, spinal cord injuries, neurological disorders, and 100+ other incapacitating conditions, all of which are covered at - click-on 'Diseases Treated.'"

RSCI's world-leading stem cell treatment experts are as follows:

SAB chairman Dr. Kitipan V. Arom, M.D., Ph.D., FACS, FACC, FACCP, FRCST, established an innovative stem cell treatment program at Bangkok Heart Hospital (BHH) and may be the only doctor in the world to successfully inject RSC directly into the heart muscles of more than 120 late-stage heart patients. Dr. Arom, associate professor of surgery and chief cardiothoracic surgeon at BHH, previously served in many capacities with several hospitals in the Minneapolis/St. Paul area, founded the Minneapolis Heart Institute & Minneapolis Heart Institution Foundation and is currently the President of the Society of Thoracic Surgeons of Thailand.

Dr. Roberto Jorge Fernandez - Vina, M.D. is known for his innumerable cardiology advances, is an authority on the utilization of RSC treatment of Type-2 diabetes and is the first and only known person with a successful clinical trial on helping Type-2 diabetes with repair stem cell treatment. He has treated hundreds of patients with RSC for heart disease, Type-2 diabetes and emphysema; both in his clinic in Argentina and in clinics in other Latin American countries. He is on the verge of another discovery for the most difficult to treat common disease of all, diabetes Type-1.

Professor Shimon Slavin, M.D., an expert bone marrow transplantation scientist and clinician, is world-famous for his innovative clinical application of cell-mediated immunotherapy for the treatment of hematological malignancies, solid tumors, immune disorders and a broad spectrum of non-malignant conditions treatable by stem cell transplantation. He and his team are the first known in the world to treat multiple sclerosis and amyotropic lateral sclerosis patients by injecting their spinal fluid with large numbers of repair stem cells (mesenchymal stromal stem cells) taken from their bone marrow and multiplied in culture. Dr. Slavin is the medical & scientific director of the newly established International Center for Cell Therapy & Cancer (ICTC) at the Tel Aviv (Sourasky) Medical Center in Israel.

Dr. Carlos Lima, M.D., one of the foremost neuropathologist experts in RSC treatments, rejected traditional bone marrow stem cells as a too limited source for the neurological stem cells required to repair injured spinal cords. Using olfactory stem cells harvested from the patients' own nose, Dr. Lima transplants the cells at the spinal cord break utilizing the successful OMA transplant surgical procedure he developed. Dr. Lima is the only doctor in the world whose treatments have created the neurological redevelopment required to allow some paraplegics to engage in extensive rehabilitation therapy, rise from their wheelchairs and walk.

Dr. Zannos G. Grekos, M.D., Director of Cardiology & Vascular Disease at Metropolitan Hospital - Santiago, Dominican Republic, is a RSC innovator. In April 2008 he saved a young meningitis patient's arms and legs from amputation and in May he saved a young cardiomyopathy patient with serious complications by developing a new multi-faceted comprehensive repair stem cell treatment procedure. He has collaborated with the major treatment centers in Asia, been active in both the development of research and treatment protocols and consults with patients throughout the world. Dr. Grekos utilizes RSC to treat pulmonary hypertension and fibrosis, heart and peripheral vascular diseases and diabetes.

Visit and click-on "Science Advisory Board" for more information about each of these five leaders, now treating over 100 different medical conditions.

SOURCE The Repair Stem Cell Institute LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
2. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
3. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
4. Remergent(R) Announces the Launch of Four New Products Pioneers of DNA Repair Expand Anti-Aging Line
5. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
6. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
7. CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair
8. Real-time observation of the DNA-repair mechanism
9. Worldwide Center for Adult Stem Cell Education LLC Changes Name to The Repair Stem Cell Institute LLC
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
Breaking Biology News(10 mins):